Antitumor activity and immune-related gene expression changes following recombinant Mycobacterium smegmatis treatment in a mouse model of bladder cancer

Bladder cancer requires additional therapeutic strategies because of frequent recurrence and progression risk. We evaluated recombinant Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor–interleukin-7 fusion protein (rSmeg-hMIF-hIL-7) in a syngeneic subcutaneous MBT-2 bladder cancer model. Among mice that developed measurable tumors, intraperitoneally treated mice showed reduced tumor growth and longer endpoint-free survival, defined as time to death or humane-endpoint euthanasia. RNA sequencing of four control and three treated tumors identified 116 differentially expressed genes at a fold-change magnitude ≥ 2 and false discovery rate (FDR) < 0.05. Enrichment analyses highlighted immune-related transcriptional differences, although tissue-collection timing and tumor burden limited their attribution to treatment. Cross-species expression comparison identified five exploratory candidates: CCL15, CCRL2, ST3GAL5, SIGLEC6, and TMEM255A. Four showed FDR-significant survival associations in exploratory unadjusted Cox analyses within the same TCGA-BLCA cohort. Expression patterns concordant with those in treated mouse tumors were also associated with papillary histology. RT-qPCR using the same biological samples supported increased Ccl6 and St3gal5 expression after multiple-testing correction. These findings support the antitumor potential of rSmeg-hMIF-hIL-7 and provide exploratory links between murine tumor transcriptional differences and human bladder cancer characteristics.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-16
DOI
https://doi.org/10.1038/s41598-026-80452-x
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antitumor activity and immune-related gene expression changes following recombinant Mycobacterium smegmatis treatment in a mouse model of bladder cancer

Baek Gil Kim, Dongwook Song, Young Deuk Choi, Jae Won Park et al.
3 links
Scientific Reports
Bladder and Urothelial Cancer Treatments
article

Antitumor activity and immune-related gene expression changes following recombinant Mycobacterium smegmatis treatment in a mouse model of bladder cancer

Baek Gil Kim, Dongwook Song, Young Deuk Choi, Jae Won Park, Hyunho Han, Gisub Choi
article en

Abstract

Bladder cancer requires additional therapeutic strategies because of frequent recurrence and progression risk. We evaluated recombinant Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor–interleukin-7 fusion protein (rSmeg-hMIF-hIL-7) in a syngeneic subcutaneous MBT-2 bladder cancer model. Among mice that developed measurable tumors, intraperitoneally treated mice showed reduced tumor growth and longer endpoint-free survival, defined as time to death or humane-endpoint euthanasia. RNA sequencing of four control and three treated tumors identified 116 differentially expressed genes at a fold-change magnitude ≥ 2 and false discovery rate (FDR) < 0.05. Enrichment analyses highlighted immune-related transcriptional differences, although tissue-collection timing and tumor burden limited their attribution to treatment. Cross-species expression comparison identified five exploratory candidates: CCL15, CCRL2, ST3GAL5, SIGLEC6, and TMEM255A. Four showed FDR-significant survival associations in exploratory unadjusted Cox analyses within the same TCGA-BLCA cohort. Expression patterns concordant with those in treated mouse tumors were also associated with papillary histology. RT-qPCR using the same biological samples supported increased Ccl6 and St3gal5 expression after multiple-testing correction. These findings support the antitumor potential of rSmeg-hMIF-hIL-7 and provide exploratory links between murine tumor transcriptional differences and human bladder cancer characteristics.

Scientific Reports
Yonsei University (KR), National Health Insurance Service Ilsan Hospital (KR), National Health Insurance Service (KR), Yonsei University Health System (KR)
Seoul National University, Yonsei University, Yonsei University College of Medicine
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon